OncoMatch/Clinical Trials/NCT05260528
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Is NCT05260528 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cytarabine and Idarubicin and CPX-315 for acute myeloid leukemia.
Treatment: Cytarabine and Idarubicin · CPX-315 — The trial is a randomized, open-label phase II study comparing CPX-351 vs conventional intensivechemotherapy in patients with newly diagnosed de novo AML and intermediate- or adverse-risk genetics
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 wild-type
Required: NPM1 wild-type
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: short course hydroxyurea in patients presenting with high WBC count and/or tumor symptoms
Not previously treated except for short course hydroxyurea in patients presenting with high WBC count and/or tumor symptoms
Cannot have received: radiation therapy
Exception: local radiotherapy for prostate cancer
Prior history of radiation therapy or chemotherapy for a solid tumor or lymphoma (exceptions to be considered: local radiotherapy for prostate cancer)
Lab requirements
Blood counts
as indicated detailed with laboratory values in the section IV of the protocol
Kidney function
as indicated detailed with laboratory values in the section IV of the protocol
Liver function
as indicated detailed with laboratory values in the section IV of the protocol
Cardiac function
Cardiac ejection fraction <50% or considered as abnormal by echocardiography or MUGA scan [excluded]
Patient must have adequate organ function as indicated detailed with laboratory values in the section IV of the protocol; Cardiac ejection fraction <50% or considered as abnormal by echocardiography or multi-gated acquisition (MUGA) scan [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify